Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
In some aspects, the present invention provides compositions and methods (e.g. methods of treating, preventing, making, etc.) comprising compstatin analogs. In some embodiments, compstatin analogs comprise a linear PEG moiety having a molecular weight of 40 kDa and coupled to each of two compstatin analog moieties; wherein each compstatin analog moiety is a CA28-AEEAc-Lys moiety, the linear PEG moiety is coupled to the Lys side chain of each CA28-AEEAc-Lys moiety via a carbamate and each CA28-AEEAc-Lys moiety is Ac-Ile-Cys*-Val-(1Me)Trp-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys*-Thr-[NH-CH2CH2OCH2CH2OCH2-C(═O)]-Lys-NH2 (SEQ ID NO: 51); wherein the Cys* groups are joined by a disulfide bond.
1. A compstatin analog comprising:
a linear PEG moiety having an average molecular weight of about 40 kDa and coupled to each of two compstatin analog moieties; wherein:
i) each compstatin analog moiety is a CA28-AEEAc-Lys moiety;
ii) the linear PEG moiety is coupled to the Lys side chain of each CA28-AEEAc-Lys moiety via a carbamate; and
iii) each CA28-AEEAc-Lys moiety is Ac-Ile-Cys*-Val-(1Me)Trp-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys*-Thr-[NH-CH 2 CH 2 OCH 2 CH 2 OCH 2 -C(═O)]-Lys-NH 2 (SEQ ID NO: 51); wherein the Cys* groups are joined by a disulfide bond.
2. A compstatin analog obtained by coupling two CA28-AEEAc-Lys moieties to a bifunctional linear PEG moiety having an average molecular weight of about 40 kDa; wherein:
i) the bifunctional linear PEG moiety is coupled to the Lys side chain of each CA28-AEEAc-Lys moiety via a carbamate; and
ii) each CA28-AEEAc-Lys moiety is Ac-Ile-Cys*-Val-(1Me)Trp-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys*-Thr-[NH—CH 2 CH 2 OCH 2 CH 2 OCH 2 —C(═O)]-Lys-NH 2 (SEQ ID NO: 51); wherein the Cys* groups are joined by a disulfide bond.
3. The compstatin analog according to claim 2 , wherein said bifunctional linear PEG moiety is of Formula IVa:
wherein n is between 30 and 3000.
4. A composition comprising the compstatin analog of claim 1 , and a pharmaceutically acceptable carrier.
5. A method of reducing the sensitivity of a cell or organ to complement-dependent damage, the method comprising:
administering to a subject the compstatin analog of claim 1 .
6. A method of treating or preventing a complement-mediated disorder in a subject in need thereof, the method comprising administering to the subject the compstatin analog of claim 1 .
7. The method of claim 6 wherein the complement-mediated disorder is age-related macular degeneration (AMD) or geographic atrophy (GA).
8. The method of claim 7 , wherein the compstatin analog is administered to the eye of the subject.
9. The method of claim 8 , wherein the compstatin analog is administered by intravitreal administration.
10. The method of claim 6 , wherein the complement-mediated disorder is transplant rejection; ischemia/reperfusion injury; haemolytic anemia; an autoimmune disease; neuropathic pain; membranoproliferative glomerulitis; neuromyelitis optica; spinal cord injury; asthma, paroxysmal nocturnal hemoglobinuria (PNH); or chronic obstructive pulmonary disease (COPD).
11. The method of claim 10 , wherein the compstatin analog is administered by subcutaneous or intravenous administration.